Pancreatic cancer is digestive cancer with limited therapeutic options and a poor outcome. Pancreatic cancer has a high mortality rate, with a 5-year survival rate of less than 5%. The median survival after metastasis of the disease is less than 6 months. Studies have revealed that the standard treatment, including palliative chemotherapy or immunotherapy, is not significantly effective for pancreatic cancer. Herein, we report a case of pancreatic cancer who benefited from a combination of anti-PD-1 immunotherapy and chemotherapy.

中文翻译：

---

肿瘤突变负荷作为胰腺癌免疫治疗的标志物：病例报告和文献综述。

胰腺癌是消化道癌症，治疗选择有限且预后不佳。胰腺癌死亡率较高，5年生存率不足5%。疾病转移后的中位生存期不到6个月。研究表明，标准治疗，包括姑息化疗或免疫疗法，对胰腺癌的疗效并不显着。在此，我们报告了一例胰腺癌患者，该患者受益于抗 PD-1 免疫疗法和化疗的联合治疗。